We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Under the agreement, AMAG will receive the right to commercialise and develop Intrarosa in the US to treat VVA and female sexual dysfunction (FSD) and pay $50m to Endoceutics at closing.